Grant: Master's Award: Canada Graduate Scholarships
University of Ottawa
$17,500.00
In vivo regenerative effects of exosomal Wnt7a : a potential systemic treatment for Duchenne Muscular Dystrophy
FY 2018-19
Summary
Duchenne Muscular Dystrophy (DMD) is a devastating genetic muscular disorder that manifests during childhood by progressive debilitating muscle wasting and death around the second decade of life. It affects 1 of 3500 newborn boys. No effective therapies are currently available. Our long-term goal is the development of an efficient therapy for DMD. Our laboratory discovered the interaction of protein Wnt7a with its receptor Fzd7 is an important cellular mechanism that promotes muscle regeneration. Wnt7a treatment in mdx mice, a mouse model of DMD, results in increased numbers of muscle stem cells and myofiber enlargement resulting in a significant increase in strength. These findings provide evidence that Wnt7a is an outstanding candidate for treatment of DMD.
A major limitation to the use of Wnt7a is it can only be delivered by direct intramuscular injections, as it cannot travel through the bloodstream. Recently, we have shown that Wnt7a is also secreted from injured muscle tissue in exosomes, small vesicles used for cellular communication. Excitingly, exosomes are able to travel in the bloodstream. We hypothesize that exosomes will allow for systemic delivery of Wnt7a to muscle stem cells and improve muscle regeneration in DMD.
First, we will perform intramuscular injections of exosomal Wnt7a to evaluate the local regenerative effect in injured muscle. With this confirmation, we will progress to a systemic treatment by injecting intravenously through the tail vein. We will then assess the muscle regeneration after treatment on a molecular level in the muscle fibers and on a systemic level by analyzing the performance and characteristics of different muscle groups. Once these trials have been successful, we will transition to treating mdx mice in future
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
406438
Name
Fisher Solomon
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
In vivo regenerative effects of exosomal Wnt7a : a potential systemic treatment for Duchenne Muscular Dystrophy
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Duchenne Muscular Dystrophy; Exosomes; Muscle Stem Cells; Skeletal Muscle
Abstract
Duchenne Muscular Dystrophy (DMD) is a devastating genetic muscular disorder that manifests during childhood by progressive debilitating muscle wasting and death around the second decade of life. It affects 1 of 3500 newborn boys. No effective therapies are currently available. Our long-term goal is the development of an efficient therapy for DMD. Our laboratory discovered the interaction of protein Wnt7a with its receptor Fzd7 is an important cellular mechanism that promotes muscle regeneration. Wnt7a treatment in mdx mice, a mouse model of DMD, results in increased numbers of muscle stem cells and myofiber enlargement resulting in a significant increase in strength. These findings provide evidence that Wnt7a is an outstanding candidate for treatment of DMD.
A major limitation to the use of Wnt7a is it can only be delivered by direct intramuscular injections, as it cannot travel through the bloodstream. Recently, we have shown that Wnt7a is also secreted from injured muscle tissue in exosomes, small vesicles used for cellular communication. Excitingly, exosomes are able to travel in the bloodstream. We hypothesize that exosomes will allow for systemic delivery of Wnt7a to muscle stem cells and improve muscle regeneration in DMD.
First, we will perform intramuscular injections of exosomal Wnt7a to evaluate the local regenerative effect in injured muscle. With this confirmation, we will progress to a systemic treatment by injecting intravenously through the tail vein. We will then assess the muscle regeneration after treatment on a molecular level in the muscle fibers and on a systemic level by analyzing the performance and characteristics of different muscle groups. Once these trials have been successful, we will transition to treating mdx mice in future
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Fisher, Solomon
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~